Effect of lipid composition on incorporation of trastuzumab-PEG-lipid into nanoliposomes by post-insertion method: physicochemical and cellular characterization

References

• Allen TM, Brandeis E, Hansen CB, et al. (1995). A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta (BBA) Biomembranes 1237:99–108
   PubMed Web of Science ®Google Scholar
• Allen TM, Sapra P, Moase E. (2002). Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 7:889–94
   PubMed Web of Science ®Google Scholar
• Ansell S, Harasym T, Tardi P, et al. (2000). Antibody conjugation methods for active targeting of liposomes. In: Francis GE, Delgado C, eds. Drug targeting. Totowa (NJ): Humana Press
   Google Scholar
• Baselga J. (2001). Clinical trials of Herceptin (trastuzumab). Eur J Cancer 37:18–24
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Albanell J, et al. (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–31
   PubMed Web of Science ®Google Scholar
• Benzinger P, Martiny-Baron G, Reusch P, et al. (2000). Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro. Biochim Biophys Acta (BBA) Biomembranes 1466:71–8
   PubMed Web of Science ®Google Scholar
• Bligh EG, Dyer WJ. (1959). A rapid method of total lipidextraction and purification. Can J Biochem Physiol 37:911–17
   PubMedGoogle Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–54
   PubMed Web of Science ®Google Scholar
• Camirand A, Lu Y, Pollak M. (2002). Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Int Med J Exp Clin Res 8:521–6
   Google Scholar
• Chen JS, Lan K, Hung MC. (2003). Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Update 6:129–36
   PubMed Web of Science ®Google Scholar
• Cheng WWK, Allen TM. (2008). Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab′ fragments and single chain Fv. J Control Release 126:50–8
   PubMed Web of Science ®Google Scholar
• Chernomordik L. (1996). Non-bilayer lipids and biological fusion intermediates. Chem Phys Lipids 81:203–13
   PubMed Web of Science ®Google Scholar
• Cirstoiu-Hapca A, Buchegger F, Bossy L, et al. (2009). Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci 38:230–7
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–48
   PubMed Web of Science ®Google Scholar
• Daugherty AL, Mrsny RJ. (2006). Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58:686–706
   PubMed Web of Science ®Google Scholar
• De Menezes DEL, Pilarski LM, Allen TM. (1998). In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320–30
   PubMed Web of Science ®Google Scholar
• Elbayoumi T, Torchilin V. (2008). Tumor-targeted immuno-liposomes for delivery of chemotherapeutics and diagnostics. J Pharm Innov 3:51–8
   Google Scholar
• Ellman, GL. (1959). Tissue sulphydryl groups. Arch Biochem Biophys 82:70–7
   PubMed Web of Science ®Google Scholar
• Fredika MR, Mauro F. (2006). Introduction and rationale for nanotechnology in cancer therapy. Nanotechnology for Cancer Therapy. Boca Raton (FL): CRC Press
   Google Scholar
• Garbuzenko O, Barenholz Y, Priev A. (2005). Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 135:117–29
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Davis C. (1979). Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochem Biophys Res Com 89:1287–93
   PubMed Web of Science ®Google Scholar
• Hamilton A, Piccart M. (2000). The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11:647–63
   PubMed Web of Science ®Google Scholar
• Hansen CB, Kao GY, Moase EH, et al. (1995). Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta (BBA) Biomembranes 1239:133–44
   PubMed Web of Science ®Google Scholar
• Harding JA, Engbers CM, Newman MS, et al. (1997). Immunogenicity and pharmacokinetic attributes of poly (ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta (BBA) Biomembranes 1327:181–92
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Lewis GD, Winget M, et al. (1989). P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165–72
   PubMed Web of Science ®Google Scholar
• Hynes NE, Stern DF. (1994). The biology of erbB-2/nue/HER-2 and its role in cancer. Biochim Biophys Acta (BBA) Reviews on Cancer 1198:165–84
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1:297–315
   PubMed Web of Science ®Google Scholar
• Jerome L, Alami N, Belanger S, et al. (2006). Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2 overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 66:7245–52
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, et al. (1997). Sterically stabilized anti-HER2 immunoliposomes:  design and targeting to human breast cancer cells in vitro. Biochemistry 36:66–75
   PubMed Web of Science ®Google Scholar
• Lewis GD, Figari I, Fendly B, et al. (1993). Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255–63
   PubMed Web of Science ®Google Scholar
• Lu J, Jeon E, Lee BS, et al. (2006). Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes. J Control Release 110:505–13
   PubMed Web of Science ®Google Scholar
• Maruyama K, Takizawa T, Takahashi N, et al. (1997). Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Adv Drug Deliv Rev 24:235–42
   Web of Science ®Google Scholar
• Mcmullen TPW, Mcelhaney RN. (1996). Physical studies of cholesterol-phospholipid interactions. Curr Opin Colloid Interface Sci 1:83–90
   Web of Science ®Google Scholar
• Mercadal M, Carrion C, Domingo JC, et al. (1998). Preparation of immunoliposomes directed against CD34 antigen as target. Biochim Biophys Acta (BBA) Biomembranes 1371:17–23
   PubMed Web of Science ®Google Scholar
• Milella M, Trisciuoglio D, Bruno T, et al. (2004). Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells. Clin Cancer Res 10:7747–56
   PubMed Web of Science ®Google Scholar
• Moreira J, Ishida T, Gaspar R, Allen T. (2002). Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 19:265–9
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. (2003). HER-2-targeted therapy lessons learned and future directions. Clin Cancer Res 9:5078–84
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232:123–38
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, et al. (2006). Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–80
   PubMedGoogle Scholar
• Niehans GA, Singleton TP, Dykoski D, Kiang DT. (1993). Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85:1230–5
   PubMed Web of Science ®Google Scholar
• Nielsen UB, Kirpotin DB, Pickering EM, et al. (2002). Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (BBA) 1591:109–18
   PubMed Web of Science ®Google Scholar
• Nobs L, Buchegger F, Gurny R, Allemann E. (2004). Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 93:1980–92
   PubMed Web of Science ®Google Scholar
• Pan X, WUu G, Yang W, et al. (2007). Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjugate Chem 18:101–8
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–81
   PubMed Web of Science ®Google Scholar
• Park JW, Kirpotin DB, Hong K, et al. (2001). Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95–113
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Pegram MD, Finn RS, et al. (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER2 receptor and DNA-reactive drugs. Oncogen 17:2235–49
   PubMed Web of Science ®Google Scholar
• Price ME, Cornelius RM, Brash JL. (2001). Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim Biophys Acta (BBA) Biomembranes 1512:191–205
   PubMed Web of Science ®Google Scholar
• Sapra P, Moase EH, Ma J, Allen TM. (2004). Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments. Clin Cancer Res 10:1100–11
   PubMed Web of Science ®Google Scholar
• Sawant RR, Torchilin VP. (2012). Challenges in development of targeted liposomal therapeutics. AAPS J 14:303–15
   PubMed Web of Science ®Google Scholar
• Shmeeda H, Tzemach D, Mak L, Gabizon A. (2009). Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release 136:155–60
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–92
   PubMed Web of Science ®Google Scholar
• Steinhauser I, Spankuch B, Strebhardt K, Langer K. (2006). Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27:4975–83
   PubMed Web of Science ®Google Scholar
• Stewart JCM. (1980). Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104:10–14
   PubMed Web of Science ®Google Scholar
• Struck DK, Hoekstra D, Pagano RE. (1981). Use of resonance energy transfer to monitor membrane fusion. Biochemistry 20:4093–9
   PubMed Web of Science ®Google Scholar
• Sułkowski WW, Pentak D, Nowak K, Sulkowska A. (2005). The influence of temperature, cholesterol content and pH on liposome stability. J Mol Structure 744:737–47
   Web of Science ®Google Scholar
• Tokuda Y. (2003). Antibodies as molecular target-based therapy: trastuzumab. Int J Clin Oncol 8:224–9
   PubMedGoogle Scholar
• Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–60
   PubMed Web of Science ®Google Scholar
• Tripathy D. (2005). Targeted therapies in breast cancer. Breast J 11:30–5
   Web of Science ®Google Scholar
• Twentyman PR, Luscombe M. (1987). A study of some variables in a tetrazolium dye (MTT) based aaay for cell growth and chemosensitivity. Br J Cancer 56:279–85
   PubMed Web of Science ®Google Scholar
• Vogel CL, Colobeigh MA, Tripathy D, et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2 for metastatic breast cancer. J Clin Oncol 20:719–26
   PubMed Web of Science ®Google Scholar
• Waritlick H, Michaelis K, Balthazar S, et al. (2004). Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 12:461–71
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Gelmon KA, Masin D, Bally MB. (2003). Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3:261–71
   PubMedGoogle Scholar
• Wiig H, Gyenge CC, Tenstad O. (2005). The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol 567:557–67
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, et al. (2007a). Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169–77
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, et al. (2007b). Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 24:2402–11
   PubMed Web of Science ®Google Scholar